There’s a swirl of controversy around FDA’s approval of Relyvrio, a new drug indicated for ALS (amyotrophic lateral sclerosis), often called Lou Gehrig’s Disease. But there are also pricing and reimbursement issues the drug will face as its sponsor, Amylyx Pharmaceuticals, pursues market uptake.
Newly Approved ALS Drug Relyvrio To Face Its Next Challenge: Pricing And Reimbursement
